Clinical trial NCT04356014: Telangiectatic Palmoplantar Keratoderma in Systemic and Subacute Lupus Erythematosus
Official title: Telangiectatic Palmoplantar Keratoderma in Systemic and Subacute Lupus Erythematosus : to a Form of Lichen Planus-like Lupus Erythematosus ?
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Systemic Lupus Erythematosus
Lichen Planus
Keywords: Palmoplantar keratoderma with livid telangiectatic erythema
Systemic lupus
Subacute lupus erythematosus
Lead sponsor: University Hospital, Montpellier
Sponsor class: OTHER
First posted: 2020-04-21
Enrollment: 14
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients suffering from SLE or SCLE with palmar and or plantar keratoderma with livid telangiectatic erythema

Brief summary: Palmoplantar keratoderma (PPK) associated to livid telangiectatic erythema during systemic lupus erythematosus (SLE) and subacute cutaneous lupus erythematosus (SCLE) is a rare phenomenon seldom reported in literature. The investigators hypothesize that clinic-immunologic assessment and detailed investigation of cutaneous biopsy specimen of PPK and erythema of patients suffering from SLE and SCLE could lead to determine more precisely nosological settings of this injury. Report the different therapeutics with efficacy assessment could be helpful to highlight useful treatment for these patients.

Detailed description: Context: Palmoplantar keratoderma (PPK) associated to livid telangiectatic erythema during systemic lupus erythematosus (SLE) is a rare phenomenon seldom reported in literature. To our knowledge no case has been described in subacute cutaneous lupus erythematosus (SCLE) so far. Pathogeny and etiologic origin are not clear: it could be no-specific cutaneous manifestation of SLE, verrucous chilblain lupus, lichen planus, discoid lupus erythematosus lesions, overlap syndrome or coexistence of both diseases.

Objective:

1. Determine clinical immunological and histopathological features of patients with PPK and livid telangiectatic erythema-associated suffering from SLE and SCLE
2. Describe the different therapeutics used and efficacy assessment Methods: Multicentric retrospective descriptive study reporting 14 patients with SLE or SCLE suffering from an acral livid erythematosus keratoderma, with clinical data regarding lupus erythematosus and acral keratoderma, immunological blood samples findings and histopathological results of keratoderma and livid erythema biopsies with direct immunofluorescence if performed. The treatments set down in order to heal are noted followed by efficacy assessment: total failure, partial remission, complete remission.

Eligibility criteria: Inclusion criteria:

* \> 18 years old
* suffering from SLE or SCLE according to 2019 ACR/EULAR criteria
* With palmar and or plantar keratoderma with livid telangiectatic erythema

Exclusion criteria:

* \< 18 years old
* suffering from lupus lesions without SLE or SCLE criteria
* without palmar and or plantar keratoderma with livid telangiectatic erythema

Primary outcomes:
measure: Determine clinic immunologic features
timeFrame: 1 day
measure: Determine clinic histopathologic features
timeFrame: 1 day
Secondary outcomes:
measure: Different therapeutics used
timeFrame: 1 day
measure: Different therapeutics efficacy assessment
timeFrame: 1 day
Other outcomes:
Locations:
city: Montpellier
country: France
facility: Uh Montpellier
Study officials:
affiliation: University Hospitals of Montpellier
name: Didier BESSIS, PhD
role: STUDY_DIRECTOR
References: